Assessing Safety of Fibroblast Cell Therapy in Multiple Sclerosis: Hamid Khoja, PhD

Video

The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology in MS.

“What we’ve seen in our limited clinical trial is that these tolerogenic fibroblasts, or CybroCell, we don’t see any side effects, or we haven’t seen any side effects.”

This content originally appeared on our sister site, NeurologyLive.

Fibroblast cell technology seems to be safe for use in patients with multiple sclerosis (MS) and may offer a unique treatment approach. Hamid Khoja, PhD, chief scientific officer, FibroBiologics, discussed the technology, dubbed CYMS101, and the limited clinical trial that evaluated its safety.

Kohja discussed how patients treated with a 1-time infusion of CYMS101 did not experience any adverse events (AEs), unlike those treated with humanized monoclonal antibodies, although he did note the small scale of the study,

Patients enrolled in the safety study were monitored post-infusion for 4 hours and then at 4-week intervals for complete blood count and blood chemistry, where investigators again did not notice a difference. While experts opted for a single dose in the initial study, in the phase 1/2 clinical trial, multiple doses will be assessed, and investigators will look at multiple concentrations of cells to determine efficacy and safety. According to Khoja, FibroBiologics is aiming for a staggered approach to the clinical trial and anticipates filing an investigational new drug application in the third quarter of 2022.

Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Related Content
© 2025 MJH Life Sciences

All rights reserved.